Kiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 1-Year Low at $8.03

Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) reached a new 52-week low on Wednesday . The company traded as low as $8.03 and last traded at $8.41, with a volume of 127832 shares traded. The stock had previously closed at $8.15.

A number of research analysts have weighed in on KNSA shares. Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Friday, August 16th. ValuEngine raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush reissued a “buy” rating on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, JMP Securities dropped their price target on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $26.50.

The business has a 50-day moving average price of $9.68 and a 200 day moving average price of $13.90. The stock has a market capitalization of $505.76 million, a P/E ratio of -2.41 and a beta of -1.33.



Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. On average, equities analysts predict that Kiniksa Pharmaceuticals Ltd will post -3.47 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. First Manhattan Co. boosted its position in shares of Kiniksa Pharmaceuticals by 68.3% in the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock worth $866,000 after purchasing an additional 25,970 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals by 195.8% in the 2nd quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth approximately $474,000. Morgan Stanley lifted its position in Kiniksa Pharmaceuticals by 54.2% in the 2nd quarter. Morgan Stanley now owns 60,098 shares of the company’s stock valued at $814,000 after acquiring an additional 21,130 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Kiniksa Pharmaceuticals by 14.4% in the 2nd quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock valued at $14,990,000 after acquiring an additional 139,072 shares in the last quarter. 30.22% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Read More: Market Perform

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.